Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003914 · ClinicalTrials.gov registry record · Phase 2
Dolastatin 10 in Treating Patients With Advanced Kidney Cancer
A Phase 2 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00003914: Completed Phase 2 study, sponsored by Mayo Clinic.
NCT00003914 is a Phase 2 study that has completed, run by Mayo Clinic. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003914, a Phase 2 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of dolastatin 10 in treating patients with advanced kidney cancer.
Interventions
- DRUG dolastatin 10
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 1999-08 |
| Est. Completion | 2009-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003914
The ClinicalTrials.gov registry entry for NCT00003914 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which dolastatin 10 is the first listed.
NCT00003914 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003914 about?
NCT00003914 is a clinical study titled "Dolastatin 10 in Treating Patients With Advanced Kidney Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of dolastatin 10 in treating patients with advanced kidney cancer.
What is the current status of trial NCT00003914?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 1999-08. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00003914?
The interventions under investigation include: dolastatin 10 (DRUG).
Who is sponsoring clinical trial NCT00003914?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.